Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01098318 · ClinicalTrials.gov registry record · Phase 3
Rhodiola Rosea Therapy of Major Depressive Disorder
A Phase 3 study of Depression, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT01098318: Completed Phase 3 study of Depression, sponsored by University of Pennsylvania.
NCT01098318 is a Phase 3 study of Depression that has completed, run by University of Pennsylvania. The registered enrollment target is 58 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01098318, a Phase 3 study of Depression, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs. a conventional, anti-depressant drug in the treatment of major depression.
Conditions Studied
Interventions
- DRUG Sertraline
- DIETARY_SUPPLEMENT Herbal extract
- OTHER Lactose monohydrate
Study Locations (1)
Pennsylvania
- Depression Research Unit - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01098318
The ClinicalTrials.gov registry entry for NCT01098318 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Sertraline is the first listed.
NCT01098318 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01098318 about?
NCT01098318 is a clinical study titled "Rhodiola Rosea Therapy of Major Depressive Disorder". Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs. a conventional, anti-depressant drug in the treatment of major depression.
What is the current status of trial NCT01098318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2010-06. Estimated completion is 2013-07.
What conditions does trial NCT01098318 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT01098318?
The interventions under investigation include: Sertraline (DRUG), Herbal extract (DIETARY_SUPPLEMENT), Lactose monohydrate (OTHER).
Who is sponsoring clinical trial NCT01098318?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01098318 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.